Showing 2,281 - 2,300 results of 2,510 for search '"clinical researcher"', query time: 0.07s Refine Results
  1. 2281
  2. 2282
  3. 2283
  4. 2284
  5. 2285
  6. 2286
  7. 2287
  8. 2288
  9. 2289
  10. 2290
  11. 2291
  12. 2292
  13. 2293
  14. 2294
  15. 2295

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  16. 2296
  17. 2297
  18. 2298
  19. 2299
  20. 2300